Amarin Corporation plc (AMRN)
- Previous Close
0.9171 - Open
0.9600 - Bid 0.8799 x 100
- Ask 0.9258 x 200
- Day's Range
0.8708 - 0.9600 - 52 Week Range
0.6500 - 1.4900 - Volume
1,034,197 - Avg. Volume
1,746,788 - Market Cap (intraday)
349.901M - Beta (5Y Monthly) 2.01
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1500 - Earnings Date May 1, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.08
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
www.amarincorp.com275
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: AMRN
Performance Overview: AMRN
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AMRN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AMRN
Valuation Measures
Market Cap
353.67M
Enterprise Value
41.75M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.17
Price/Book (mrq)
0.64
Enterprise Value/Revenue
0.14
Enterprise Value/EBITDA
-0.82
Financial Highlights
Profitability and Income Statement
Profit Margin
-19.26%
Return on Assets (ttm)
-1.26%
Return on Equity (ttm)
-10.30%
Revenue (ttm)
306.91M
Net Income Avi to Common (ttm)
-59.11M
Diluted EPS (ttm)
-0.1500
Balance Sheet and Cash Flow
Total Cash (mrq)
320.66M
Total Debt/Equity (mrq)
1.92%
Levered Free Cash Flow (ttm)
-19.45M
Research Analysis: AMRN
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell